

COVID-19 Epidemiology in Children

Angela Myers MD, MPH
Division Director, Infectious Diseases CMKC
Professor of Pediatrics, UMKC SOM



LOVE WILL.

Children's Mercy

Disclosure

- I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME activity
- I do not intend to discuss an unapproved/investigative use of a commercial product/device in my presentation.



LOVE WILL.

Children's Mercy

Outline


- What is a coronavirus?
- Where did SARS-CoV-2 come from?
- What is the epidemiology of COVID-19 disease?
- What are the symptoms of COVID-19 in children?
- What is happening with COVID-19 variants?
- What is the epidemiology of MIS-C?



LOVE WILL.

Children's Mercy

What is a coronavirus?



LOVE WILL.

Children's Mercy

Terminology


- CoV: Coronavirus
- SARS: Severe Acute Respiratory Syndrome
- SARS-CoV-2: The virus causing COVID-19
- COVID-19 (coronavirus disease 2019): The disease caused by SARS-CoV-2

LOVE WILL.

Children's Mercy

Coronavirus

- Largest group of viruses causing respiratory and GI illness
- Enveloped, single-stranded RNA virus
- 4 distinct genera
- Named after crown-like projections
- Host specific, infecting humans and animals



CDC PHIL (NIAID). MERS-CoV. 2014

LOVE WILL.

Children's Mercy

Common coronaviruses


- 4 most common HCoV-
 - NL63, 229E, OC43, HKU1
- Winter-spring respiratory disease
- Infection early in childhood
 - Re-infection can occur
- Spread via droplets and direct/indirect contact
- GI symptoms less common

Coronavirus HCoV-229E nucleic acid detected.
 The following virus types and subtypes are identified by the Film Array Respiratory Panel: Influenza A (subtypes H1N1, H3N2, H5N1, H7N9, H10N8, Respiratory Syncytial Virus (RSV), Adenovirus, Human Metapneumovirus, Parainfluenza 1, 2, 3, 4, Rotavirus (Group A, B, C, D, E), Human Bocavirus, Human Coronavirus NL63, HCoV-229E, HCoV-OC43, and HCoV-229E.

LOVE WILL.

Children's Mercy


Where did SARS-CoV-2 come from?



LOVE WILL.

Children's Mercy

Emerging coronaviruses



LOVE WILL.

Anderson KG, et al. Nature Medicine 2020
Zhao J, et al. Front Microbiol 2020

Rasmussen, AL. Nature Medicine 2021

Children's Mercy

Emerging coronaviruses

	SARS-CoV	MERS-CoV	SARS-CoV-2
First reported	November 2002	September 2012 (April)	December 2019 (Nov)
Initial location	Southern China	Saudi Arabia (Jordan)	Wuhan, China
Cases/deaths	8,096/774 (9.5%)	1,733/678 (34.4%)	31,764,062 / 568,104 (1.8%) 142, 378, 883 / 3,041,841 (2.1%)


As of 4/20/21

LOVE WILL.

CDC
Johns Hopkins Coronavirus Resource Center

Children's Mercy

Timeline



LOVE WILL.

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline>

Children's Mercy

What is the epidemiology of COVID-19 disease?


LOVE WILL.

Children's Mercy


R0- a measure of infectivity




COVID-19 Weekly Cases US



Children represent a small proportion of COVID-19 cases and deaths nationally




Black, Hispanic/Latino, and AI/AN cases are disproportionately high




COVID-19 Cases by State

- Kansas:
- 305,861 cases
 - 9,944 hospitalizations
 - 4,953 deaths
 - 1,348,960 tested



Clusters of SARS-CoV-2 Infection Among Elementary School Educators and Students in One School District — Georgia, December 2020–January 2021

Early Release | February 22, 2021 | 770




- 9 clusters of 13 educators and 32 students
- 2 clusters with educator-to-educator transmission
 - Resulted in half of cases
- All clusters with "less than ideal distancing" (<3 feet)
- 5/9 clusters with inadequate mask usage by students

LOVE WILL.

Gold JAW et al. MMWR. 2021



Masks Work



LOVE WILL.

PLoS ONE 16(4): e0249891.



What are the symptoms of COVID-19 in children?

LOVE WILL.



Symptoms are different than adults

Table 2. Reported Symptoms at Time of Testing for Patients With a Positive Severe Acute Respiratory Syndrome Coronavirus 2 Test

Symptom	Total (n = 426)
Fever or cough or shortness of breath, n (%)	318 (74.8)
Fever, n (%)	217 (51.2)
Cough, n (%)	227 (53.3)
Shortness of breath, n (%)	92 (21.6)
Congestion or rhinorrhea, n (%)	132 (31.0)
Headache, n (%)	76 (17.8)
Gastrointestinal symptoms, n (%)	74 (17.3)
Sore throat, n (%)	59 (13.8)
Myalgias, n (%)	57 (13.4)
Fatigue, n (%)	26 (6.1)
Anorexia, n (%)	24 (5.7)
Diarrhea, n (%)	24 (5.7)
Chills, n (%)	18 (4.2)
Asymptomatic, n (%)	54 (12.7)

TABLE 2. Signs and symptoms among 385 pediatric (age <18 years) and 10,644 adult (age 18–64 years) patients* with laboratory-confirmed COVID-19 — United States, February 12–April 3, 2020

Sign/Symptom	Pediatric	Adult
Fever, cough, or shortness of breath†	213 (57)	16,167 (82)
Fever‡	160 (42)	1,794 (77)
Cough	160 (42)	6,775 (35)
Shortness of breath	39 (10)	6,674 (35)
Myalgia	64 (17)	6,713 (35)
Sore throat	21 (5)	757 (4)
Running nose§	71 (18)	5,795 (30)
Sore throat	61 (16)	4,835 (25)
Headache	37 (10)	1,746 (9)
Nausea/vomiting	37 (10)	1,329 (7)
Abdominal pain¶	27 (7)	5,953 (31)
Diarrhea	27 (7)	5,953 (31)

LOVE WILL.

MMWR Morb Mortal Wkly Rep 2020;69:422–426.
Ott W. JPDs. November 2020



Teenagers' symptoms are similar to adults

Supplementary Table 2: Symptoms of children with a positive SARS-CoV-2 test, by age

	0–12 months (n=79)	1–5 years (n=95)	6–11 years (n=134)	12–17 years (n=147)	18–21 years (n=47)
Fever or cough or shortness of breath	56 (80.0%)	77 (80.2%)	58 (75.3%)	91 (67.9%)	36 (76.6%)
Fever	45 (64.3%)	54 (56.2%)	42 (54.5%)	59 (44.0%)	17 (36.2%)
Cough	37 (52.9%)	52 (54.2%)	36 (46.8%)	66 (49.3%)	30 (63.8%)
Shortness of Breath*	12 (17.1%)	5 (5.2%)	8 (10.4%)	24 (17.9%)	13 (27.7%)
Congestion	42 (60.0%)	35 (36.5%)	13 (16.9%)	26 (19.4%)	17 (36.2%)
Sore Throat	0 (0.0%)	4 (4.2%)	14 (18.2%)	20 (14.4%)	15 (31.9%)
Anorexia	0 (0.0%)	0 (0.0%)	1 (1.3%)	11 (8.2%)	10 (20.5%)
Headache	0 (0.0%)	0 (0.0%)	2 (2.6%)	9 (6.7%)	13 (27.7%)
Chest pain	0 (0.0%)	0 (0.0%)	3 (3.9%)	16 (11.9%)	5 (10.6%)
Myalgias	0 (0.0%)	2 (2.1%)	10 (13.0%)	30 (22.4%)	15 (31.9%)
Chills	0 (0.0%)	3 (3.1%)	1 (1.3%)	8 (6.0%)	4 (8.5%)
Headache	0 (0.0%)	3 (3.1%)	19 (24.7%)	37 (27.6%)	17 (36.2%)
Gastrointestinal symptoms*	14 (20.0%)	21 (21.9%)	17 (22.1%)	17 (12.7%)	5 (10.6%)
Fatigue	2 (2.9%)	2 (2.1%)	5 (6.5%)	10 (7.5%)	7 (14.9%)
Asymptomatic	8 (11.4%)	15 (15.6%)	10 (13.0%)	19 (14.2%)	2 (4.3%)


LOVE WILL.

Ott W. JPDs. 2020



COVID-19 Severity in Children






- Most children have mild or asymptomatic infection
- Hospitalization is uncommon ~12%
- 20–30% of hospitalized children required ICU care
- No difference in hospitalization by race/ethnicity
- Death is rare 0.01% of infected children




LOVE WILL.

MMWR Morb Mortal Wkly Rep. 2020;69:422–426. JAMA Network Open. 2021;4(4):e210555.
MMWR Morb Mortal Wkly Rep. 2020;69:1081–1088. JAMA Network Open. 2021;4(4):e211578





SARS-CoV-2 Variants Circulating in US



	ORIGINAL VIRUS	B.1.1.7	B.1.351	P1
Pfizer-BioNTech	95%	Same efficacy	Reduced antibody levels	Same efficacy
Moderna	94%	Same efficacy	Reduced antibody levels	More data needed
J&J	72%*	Same efficacy	Reduced efficacy (in South Africa trials)	Reduced efficacy (in Latin America trials)
AstraZeneca	60-90%	Same efficacy	Reduced efficacy	Same efficacy

Note: *In US trials, Average of 66% efficacy with South Africa and Latin America trials included.

Source: UW Medicine; Reuters; Lancet; Lancet Preprint; BioRxiv; Moderna; Nature; New England Journal of Medicine; Imperial College London; CDC-CoV-Images.org

HSIDE R

What is the epidemiology of MIS-C?

LOVE WILL.

Children's Mercy

MIS-C Case Definition

Case Definition for Multisystem Inflammatory Syndrome in Children (MIS-C)

- An individual aged <21 years presenting with fever¹, laboratory evidence of inflammation², and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
- No alternative plausible diagnosis; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms

LOVE WILL.

<https://www.cdc.gov/mis-c/cases/index.html>

Children's Mercy

Most children do not have a preceding history of COVID-19

Table 1. Characteristics of Patients With MIS-C by Age Group, United States, March 2020 to January 2021

Variable	All MIS-C cases (N = 1733), No. (%)	Age, No. (%), y ^a 0-4 (n = 445)	5-9 (n = 588)	10-14 (n = 431)	15-17 (n = 335)	18-20 (n = 53)	P value ^b
Preceding COVID-19-like illness ^c	265 (24.7)	50 (18.1)	62 (16.4)	86 (30.7)	50 (43.9)	17 (63)	<.001
Incidence per 100,000 children	2.1	2.3	2.9	2.2	1.5	0.4	<.001

LOVE WILL.

Bojaj E et al. JAMA Pediatr. 2021

Children's Mercy

MIS-C cases across the U.S.




LOVE WILL.

<https://www.cdc.gov/mis-c/cases/index.html>

Children's Mercy

Most children are school-aged and Hispanic/Latino or Black



LOVE WILL.

<https://www.cdc.gov/mis-c/cases/index.html>


Differentiating between MIS-C and severe acute COVID-19

Table 1. Baseline Characteristics of Patients With MIS-C and Severe Acute COVID-19 and Initial Laboratory Values Within 48 Hours of Admission^{a,b,c}

Characteristic	MIS-C (n = 538)	Severe acute COVID-19 (n = 377)
Age, median (IQR), y	8.3 (4.2-11.2)	11.7 (5.2-16.6)
Race/Ethnicity, No. (%)		
White, non-Hispanic (n = 174)	421 (78.3)	109 (28.9)
Black, non-Hispanic (n = 330)	181 (33.5)	129 (34.2)
Hispanic or Latino (n = 453)	390 (72.5)	262 (69.5)
Other, non-Hispanic (n = 83)	27 (5.0)	46 (12.3)
Underlying medical conditions, No. (%)		
At least 1 underlying condition ^d	267 (49.6)	298 (79.3)
Organ systems involved, median (IQR) ^e	4.0 (3.0-5.0)	2.0 (1.0-3.0)
Symptoms and signs on presentation, No. (%)		
Constitutional	536 (99.4)	473 (95.4)
Gastrointestinal	486 (90.3)	332 (87.9)
Microcirculation	380 (70.8)	39 (10.3)
Lower respiratory	233 (43.3)	393 (104.3)

LOVE WILL.

Feldstein LR et al. JAMA. March 16, 2021



GI symptoms are common

Table 1. Characteristics of Patients With MIS-C by Age Group, United States, March 2020 to January 2021


Variable	All MIS-C cases (n = 1733), No. (%)	0-4 (n = 445)	5-9 (n = 588)	10-14 (n = 411)	15-17 (n = 293)	18-20 (n = 53)	P value ^a
Signs and symptoms							
Abdominal pain ^b	1133 (65.3)	187 (42)	475 (80.8)	336 (81.3)	223 (76.1)	37 (69.6)	<.001
Vomiting	1114 (64.3)	232 (52.1)	426 (72.4)	305 (74.2)	221 (73.7)	27 (50.9)	<.001
Diarrhea	931 (53.7)	218 (49)	331 (56.3)	246 (59.9)	155 (52.9)	30 (56.6)	.22
Rash	963 (55.6)	303 (68.1)	354 (60.2)	221 (53.8)	65 (22)	20 (37.7)	<.001
Conjunctival hyperemia	929 (53.6)	246 (55.3)	362 (61.4)	256 (62.3)	58 (19.8)	10 (18.9)	<.001
Cough	490 (28.3)	111 (24.9)	131 (22.3)	145 (35.3)	76 (25.9)	27 (50.9)	<.001
Shortness of breath ^c	475 (27.4)	67 (15.1)	141 (24)	133 (32.3)	84 (28.3)	29 (54.7)	<.001
Chest pain or tightness ^d	252 (14.5)	6 (1.3)	57 (9.7)	100 (24.3)	66 (22.5)	23 (43.4)	<.001
Clinical findings							
Hypotension	880 (50.8)	160 (36)	297 (50.5)	283 (68.9)	109 (37.2)	29 (54.7)	<.001
Shock	638 (36.8)	110 (24.7)	218 (37.1)	207 (50.4)	88 (29.7)	22 (41.5)	<.001

LOVE WILL.

Belay E et al. JAMA Peds April 6, 2021



Most children with MIS-C recover

Figure 4. Cardiovascular Outcomes of Patients With MIS-C^a

LOVE WILL.

Feldstein LR et al. JAMA. March 16, 2021



Conclusions

- CoV can infect animals and humans
- Children can transmit the virus that causes COVID-19
- Children less commonly infected than adults; & are often mild or asymptomatic
- Variant viruses develop with ongoing virus replication
- A small proportion of children get severe acute COVID-19
- Children who get MIS-C may not have had significant COVID-19 infection

LOVE WILL.

<https://www.cdc.gov/mis-c/cases/index.html>


Questions?



LOVE WILL.

<https://www.cdc.gov/mis-c/cases/index.html>
